It is well reported that levels of C-Alb or HCit differ significantly between individuals who experience meaningful clinical outcomes and those who do not (e.g., mortality, CKD progression, cardiovascular events, even anemia and erythropoietin resistance) [1]. Here, EPO is linked to chronic kidney disease.